VLS Valneva SE

Declaration of shares and voting rights April 30, 2024 - VALNEVA SE

Declaration of shares and voting rights April 30, 2024 - VALNEVA SE

VALNEVA

Declaration of shares and voting rights

April 30, 2024

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment B

Declaration date: May 6, 2024

Number of shares

composing the share capital of Valneva
Total number of voting rights including suspended voting rights* Description of the change Date on which this change was recognized Total number of voting rights excluding suspended voting rights**
 



139,276,901



ordinary shares with a par value of €0.15 each
158,384,922  



Transfer into bearer form of 1,000,000 shares with double voting rights



 



Double voting rights granted on 1,350 ordinary shares
April 26, 2024



 



Between April 4 &

April 29, 2024
158,260,600

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.

Attachment



EN
06/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

Oscar Haffen Lamm
  • Oscar Haffen Lamm

Additional positive data in adolescents to support Ixchiq label extens...

Valneva reported additional positive phase 3 data for its single-shot Ixchiq vaccine (CHIKV) in adolescents. Following the initial analysis up to Day 29 post-vaccination, the most recent analysis of the study VLA1553-321 evaluated the safety and immunogenicity six months (Day 180) after vaccination

 PRESS RELEASE

Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents f...

Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine Results Intended to Support Filing for Potential Label Extension for Use in Adolescents Saint-Herblain (France), May 13, 2024 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive pivotal Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine. Following the initial analysis up to Day 29 post-vaccination, the most recent analysis of study VLA1553-321 evaluated the safety and immunogenicity six months (D...

Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures

Valneva : Disappointing Q1 due to supply constraints – guidance confir...

>Top and bottom line below expectations - Q1 revenues came in 2% lower at € 32.8m (-24% vs cs) with product sales stable at € 32.1m (-21% vs cs). This disappointing performance can mainly be attributed to supply issue for Ixiaro which showed a decline of 5% (-34% vs cs). Dukoral saw sales grow by 10% to € 11.3m (+18% vs cs) underpinned by a recovery in the traveller market. As expected, third-party distribution (-9%, -33% vs Cs) suffered from supply constraints for t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch